ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Parenteral PrEP Market Research Report 2026
Published Date: 2026-02-10
|
Report Code: QYRE-Auto-30J18115
Home | Market Reports | Health| Pharmacy
Global Parenteral PrEP Market Research Report 2024
BUY CHAPTERS

Global Parenteral PrEP Market Research Report 2026

Code: QYRE-Auto-30J18115
Report
2026-02-10
Pages:104
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Gilead Sciences
ViiV Healthcare

Parenteral PrEP Market Size

The global Parenteral PrEP market was valued at US$ 291 million in 2025 and is anticipated to reach US$ 781 million by 2032, at a CAGR of 15.1% from 2026 to 2032.

Parenteral PrEP Market

Parenteral PrEP Market

The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Parenteral PrEP competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
Parenteral PrEP refers to HIV pre-exposure prophylaxis delivered via non-enteral routes—most commonly long-acting intramuscular injections, and in broader usage also implants or other sustained-release parenteral platforms—designed to maintain protective drug concentrations over extended intervals before potential HIV exposure occurs. In practice today, the term largely maps to long-acting injectable PrEP (e.g., long-acting cabotegravir), with the wider pipeline including implants and long-acting biologics. The central problem it addresses is not the pharmacologic efficacy of PrEP per se (daily oral PrEP is highly effective when taken as prescribed), but the implementation gap: adherence burden, missed doses, access continuity, and privacy/stigma concerns that can reduce real-world effectiveness; by shifting protection from “remember a pill every day” to “receive a dose every 1–2 months (or longer),” parenteral PrEP aims to deliver more consistent coverage and simplify prevention for people who struggle with, dislike, or cannot safely sustain oral regimens.In 2025, the global production capacity of parenteral PrEP reached 150,000 doses, while total sales amounted to 109,800 doses. The average selling price was USD 2,650 per dose, and the gross margin of manufacturers ranged between 60% and 70%.
The current parenteral PrEP market is in a transitional phase where clinical effectiveness is well established, but health systems and delivery models are still adapting to long-acting prevention. Acceptance among clinicians, public health authorities, and at-risk communities has grown steadily, particularly in populations where daily oral PrEP has faced adherence or continuity challenges. At the same time, the market shows a clear dual-track pattern: in higher-income settings, parenteral PrEP is typically integrated into structured medical care with an emphasis on monitoring and long-term management, while in resource-limited or high-incidence settings it is often embedded within public health programs aimed at reducing population-level transmission and stigma. As a result, uptake is shaped less by lack of interest than by variation in system readiness to support repeat dosing, follow-up, and logistics.
Looking ahead, the market is expected to evolve from reliance on a single dominant modality toward a landscape where multiple long-acting technologies coexist. Injectable approaches are likely to remain central in the near term, but innovation is increasingly focused on extending dosing intervals, offering alternative delivery formats, and pairing biomedical prevention with digital follow-up and community-based services. Parenteral PrEP is gradually being repositioned from a simple substitute for oral regimens to a flexible prevention option that can be tailored to different risk profiles, life circumstances, and care settings. Over time, competitive differentiation is likely to hinge on user experience and service integration, including convenience, discretion, and reduced long-term burden on both patients and providers.
The main drivers of this market include the persistent gap between proven efficacy and real-world adherence, growing policy emphasis on sustainable HIV prevention strategies, and ongoing advances in drug formulation and delivery science. At the same time, several constraints continue to shape adoption, such as dependence on healthcare infrastructure, the need for trained personnel and regular follow-up, social stigma and uneven awareness, and concerns around long-term safety or reversibility among certain users. The interaction of these forces suggests that growth in parenteral PrEP will be evolutionary rather than abrupt, unfolding alongside broader changes in health policy, service delivery, and social acceptance rather than through rapid, uniform expansion.
This report delivers a comprehensive overview of the global Parenteral PrEP market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Parenteral PrEP. The Parenteral PrEP market size, estimates, and forecasts are provided in terms of sales volume (K Dose) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Parenteral PrEP market comprehensively. Regional market sizes by Type, by Application, by Dosing Interval, and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Parenteral PrEP manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation

Scope of Parenteral PrEP Market Report

Report Metric Details
Report Name Parenteral PrEP Market
Accounted market size in 2025 US$ 291 million
Forecasted market size in 2032 US$ 781 million
CAGR 15.1%
Base Year 2025
Forecasted years 2026 - 2032
Segment by Type
  • Cabotegravir
  • Lenacapavir
  • Other
Segment by Dosing Interval
  • Short-interval Injections
  • Monthly Injections
  • Quarterly Injections
Segment by Drug Properties
  • Original Drug
  • Generic Drug
by Application
  • Subcutaneous Use
  • Intramuscular Use
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Gilead Sciences, ViiV Healthcare
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, by Dosing Interval, etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
  • Chapter 2: Provides a detailed analysis of the competitive landscape for Parenteral PrEP manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
  • Chapter 3: Examines Parenteral PrEP sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
  • Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
  • Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
  • Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
  • Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
  • Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
  • Chapter 9: Summarizes the key findings and conclusions of the report.

FAQ for this report

How fast is Parenteral PrEP Market growing?

Ans: The Parenteral PrEP Market witnessing a CAGR of 15.1% during the forecast period 2026-2032.

What is the Parenteral PrEP Market size in 2032?

Ans: The Parenteral PrEP Market size in 2032 will be US$ 781 million.

Who are the main players in the Parenteral PrEP Market report?

Ans: The main players in the Parenteral PrEP Market are Gilead Sciences, ViiV Healthcare

What are the Application segmentation covered in the Parenteral PrEP Market report?

Ans: The Applications covered in the Parenteral PrEP Market report are Subcutaneous Use, Intramuscular Use

What are the Type segmentation covered in the Parenteral PrEP Market report?

Ans: The Types covered in the Parenteral PrEP Market report are Cabotegravir, Lenacapavir, Other

1 Parenteral PrEP Market Overview
1.1 Product Definition
1.2 Parenteral PrEP by Type
1.2.1 Global Parenteral PrEP Market Value by Type: 2025 vs 2032
1.2.2 Cabotegravir
1.2.3 Lenacapavir
1.2.4 Other
1.3 Parenteral PrEP by Dosing Interval
1.3.1 Global Parenteral PrEP Market Value by Dosing Interval: 2025 vs 2032
1.3.2 Short-interval Injections
1.3.3 Monthly Injections
1.3.4 Quarterly Injections
1.4 Parenteral PrEP by Drug Properties
1.4.1 Global Parenteral PrEP Market Value by Drug Properties: 2025 vs 2032
1.4.2 Original Drug
1.4.3 Generic Drug
1.5 Parenteral PrEP by Application
1.5.1 Global Parenteral PrEP Market Value by Application: 2025 vs 2032
1.5.2 Subcutaneous Use
1.5.3 Intramuscular Use
1.6 Global Parenteral PrEP Market Size Estimates and Forecasts
1.6.1 Global Parenteral PrEP Revenue 2021–2032
1.6.2 Global Parenteral PrEP Sales 2021–2032
1.6.3 Global Parenteral PrEP Market Average Price (2021–2032)
1.7 Assumptions and Limitations
2 Parenteral PrEP Market Competition by Manufacturers
2.1 Global Parenteral PrEP Sales Market Share by Manufacturers (2021–2026)
2.2 Global Parenteral PrEP Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Parenteral PrEP Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Parenteral PrEP, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Parenteral PrEP, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Parenteral PrEP, Product Types and Applications
2.7 Global Key Manufacturers of Parenteral PrEP, Date of Entry into the Industry
2.8 Global Parenteral PrEP Market Competitive Situation and Trends
2.8.1 Global Parenteral PrEP Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Parenteral PrEP Players Market Share by Revenue
2.8.3 Global Parenteral PrEP Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Parenteral PrEP Market Scenario by Region
3.1 Global Parenteral PrEP Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Parenteral PrEP Sales by Region: 2021–2032
3.2.1 Global Parenteral PrEP Sales by Region: 2021–2026
3.2.2 Global Parenteral PrEP Sales by Region: 2027–2032
3.3 Global Parenteral PrEP Revenue by Region: 2021–2032
3.3.1 Global Parenteral PrEP Revenue by Region: 2021–2026
3.3.2 Global Parenteral PrEP Revenue by Region: 2027–2032
3.4 North America Parenteral PrEP Market Facts & Figures by Country
3.4.1 North America Parenteral PrEP Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Parenteral PrEP Sales by Country (2021–2032)
3.4.3 North America Parenteral PrEP Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Parenteral PrEP Market Facts & Figures by Country
3.5.1 Europe Parenteral PrEP Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Parenteral PrEP Sales by Country (2021–2032)
3.5.3 Europe Parenteral PrEP Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Parenteral PrEP Market Facts & Figures by Region
3.6.1 Asia Pacific Parenteral PrEP Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Parenteral PrEP Sales by Region (2021–2032)
3.6.3 Asia Pacific Parenteral PrEP Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Parenteral PrEP Market Facts & Figures by Country
3.7.1 Latin America Parenteral PrEP Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Parenteral PrEP Sales by Country (2021–2032)
3.7.3 Latin America Parenteral PrEP Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Parenteral PrEP Market Facts & Figures by Country
3.8.1 Middle East and Africa Parenteral PrEP Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Parenteral PrEP Sales by Country (2021–2032)
3.8.3 Middle East and Africa Parenteral PrEP Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Parenteral PrEP Sales by Type (2021–2032)
4.1.1 Global Parenteral PrEP Sales by Type (2021–2026)
4.1.2 Global Parenteral PrEP Sales by Type (2027–2032)
4.1.3 Global Parenteral PrEP Sales Market Share by Type (2021–2032)
4.2 Global Parenteral PrEP Revenue by Type (2021–2032)
4.2.1 Global Parenteral PrEP Revenue by Type (2021–2026)
4.2.2 Global Parenteral PrEP Revenue by Type (2027–2032)
4.2.3 Global Parenteral PrEP Revenue Market Share by Type (2021–2032)
4.3 Global Parenteral PrEP Price by Type (2021–2032)
5 Segment by Application
5.1 Global Parenteral PrEP Sales by Application (2021–2032)
5.1.1 Global Parenteral PrEP Sales by Application (2021–2026)
5.1.2 Global Parenteral PrEP Sales by Application (2027–2032)
5.1.3 Global Parenteral PrEP Sales Market Share by Application (2021–2032)
5.2 Global Parenteral PrEP Revenue by Application (2021–2032)
5.2.1 Global Parenteral PrEP Revenue by Application (2021–2026)
5.2.2 Global Parenteral PrEP Revenue by Application (2027–2032)
5.2.3 Global Parenteral PrEP Revenue Market Share by Application (2021–2032)
5.3 Global Parenteral PrEP Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Gilead Sciences
6.1.1 Gilead Sciences Company Information
6.1.2 Gilead Sciences Description and Business Overview
6.1.3 Gilead Sciences Parenteral PrEP Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Gilead Sciences Parenteral PrEP Product Portfolio
6.1.5 Gilead Sciences Recent Developments/Updates
6.2 ViiV Healthcare
6.2.1 ViiV Healthcare Company Information
6.2.2 ViiV Healthcare Description and Business Overview
6.2.3 ViiV Healthcare Parenteral PrEP Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 ViiV Healthcare Parenteral PrEP Product Portfolio
6.2.5 ViiV Healthcare Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Parenteral PrEP Industry Chain Analysis
7.2 Parenteral PrEP Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Parenteral PrEP Production Mode & Process Analysis
7.4 Parenteral PrEP Sales and Marketing
7.4.1 Parenteral PrEP Sales Channels
7.4.2 Parenteral PrEP Distributors
7.5 Parenteral PrEP Customer Analysis
8 Parenteral PrEP Market Dynamics
8.1 Parenteral PrEP Industry Trends
8.2 Parenteral PrEP Market Drivers
8.3 Parenteral PrEP Market Challenges
8.4 Parenteral PrEP Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Gilead Sciences
ViiV Healthcare
List of Tables
 Table 1. Global Parenteral PrEP Market Value by Type (US$ Million), 2025 vs 2032
 Table 2. Global Parenteral PrEP Market Value by Dosing Interval (US$ Million), 2025 vs 2032
 Table 3. Global Parenteral PrEP Market Value by Drug Properties (US$ Million), 2025 vs 2032
 Table 4. Global Parenteral PrEP Market Value by Application (US$ Million), 2025 vs 2032
 Table 5. Global Parenteral PrEP Market Competitive Situation by Manufacturers in 2025
 Table 6. Global Parenteral PrEP Sales (K Dose) of Key Manufacturers (2021–2026)
 Table 7. Global Parenteral PrEP Sales Market Share by Manufacturers (2021–2026)
 Table 8. Global Parenteral PrEP Revenue (US$ Million) by Manufacturers (2021–2026)
 Table 9. Global Parenteral PrEP Revenue Share by Manufacturers (2021–2026)
 Table 10. Global Market Parenteral PrEP Average Price (US$/Dose) of Key Manufacturers (2021–2026)
 Table 11. Global Key Players of Parenteral PrEP, Industry Ranking, 2023 vs 2024 vs 2025
 Table 12. Global Key Manufacturers of Parenteral PrEP, Manufacturing Sites and Headquarters
 Table 13. Global Key Manufacturers of Parenteral PrEP, Product Types and Applications
 Table 14. Global Key Manufacturers of Parenteral PrEP, Date of Entry into the Industry
 Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 16. Global Parenteral PrEP Companies by Tier (Tier 1, Tier 2, Tier 3), based on Parenteral PrEP Revenue, 2025
 Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 18. Global Parenteral PrEP Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Table 19. Global Parenteral PrEP Sales by Region (K Dose), 2021–2026
 Table 20. Global Parenteral PrEP Sales Market Share by Region (2021–2026)
 Table 21. Global Parenteral PrEP Sales by Region (K Dose), 2027–2032
 Table 22. Global Parenteral PrEP Sales Market Share by Region (2027–2032)
 Table 23. Global Parenteral PrEP Revenue by Region (US$ Million), 2021–2026
 Table 24. Global Parenteral PrEP Revenue Market Share by Region (2021–2026)
 Table 25. Global Parenteral PrEP Revenue by Region (US$ Million), 2027–2032
 Table 26. Global Parenteral PrEP Revenue Market Share by Region (2027–2032)
 Table 27. North America Parenteral PrEP Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 28. North America Parenteral PrEP Sales by Country (K Dose), 2021–2026
 Table 29. North America Parenteral PrEP Sales by Country (K Dose), 2027–2032
 Table 30. North America Parenteral PrEP Revenue by Country (US$ Million), 2021–2026
 Table 31. North America Parenteral PrEP Revenue by Country (US$ Million), 2027–2032
 Table 32. Europe Parenteral PrEP Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 33. Europe Parenteral PrEP Sales by Country (K Dose), 2021–2026
 Table 34. Europe Parenteral PrEP Sales by Country (K Dose), 2027–2032
 Table 35. Europe Parenteral PrEP Revenue by Country (US$ Million), 2021–2026
 Table 36. Europe Parenteral PrEP Revenue by Country (US$ Million), 2027–2032
 Table 37. Asia Pacific Parenteral PrEP Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
 Table 38. Asia Pacific Parenteral PrEP Sales by Region (K Dose), 2021–2026
 Table 39. Asia Pacific Parenteral PrEP Sales by Region (K Dose), 2027–2032
 Table 40. Asia Pacific Parenteral PrEP Revenue by Region (US$ Million), 2021–2026
 Table 41. Asia Pacific Parenteral PrEP Revenue by Region (US$ Million), 2027–2032
 Table 42. Latin America Parenteral PrEP Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 43. Latin America Parenteral PrEP Sales by Country (K Dose), 2021–2026
 Table 44. Latin America Parenteral PrEP Sales by Country (K Dose), 2027–2032
 Table 45. Latin America Parenteral PrEP Revenue by Country (US$ Million), 2021–2026
 Table 46. Latin America Parenteral PrEP Revenue by Country (US$ Million), 2027–2032
 Table 47. Middle East and Africa Parenteral PrEP Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 48. Middle East and Africa Parenteral PrEP Sales by Country (K Dose), 2021–2026
 Table 49. Middle East and Africa Parenteral PrEP Sales by Country (K Dose), 2027–2032
 Table 50. Middle East and Africa Parenteral PrEP Revenue by Country (US$ Million), 2021–2026
 Table 51. Middle East and Africa Parenteral PrEP Revenue by Country (US$ Million), 2027–2032
 Table 52. Global Parenteral PrEP Sales (K Dose) by Type (2021–2026)
 Table 53. Global Parenteral PrEP Sales (K Dose) by Type (2027–2032)
 Table 54. Global Parenteral PrEP Sales Market Share by Type (2021–2026)
 Table 55. Global Parenteral PrEP Sales Market Share by Type (2027–2032)
 Table 56. Global Parenteral PrEP Revenue (US$ Million) by Type (2021–2026)
 Table 57. Global Parenteral PrEP Revenue (US$ Million) by Type (2027–2032)
 Table 58. Global Parenteral PrEP Revenue Market Share by Type (2021–2026)
 Table 59. Global Parenteral PrEP Revenue Market Share by Type (2027–2032)
 Table 60. Global Parenteral PrEP Price (US$/Dose) by Type (2021–2026)
 Table 61. Global Parenteral PrEP Price (US$/Dose) by Type (2027–2032)
 Table 62. Global Parenteral PrEP Sales (K Dose) by Application (2021–2026)
 Table 63. Global Parenteral PrEP Sales (K Dose) by Application (2027–2032)
 Table 64. Global Parenteral PrEP Sales Market Share by Application (2021–2026)
 Table 65. Global Parenteral PrEP Sales Market Share by Application (2027–2032)
 Table 66. Global Parenteral PrEP Revenue (US$ Million) by Application (2021–2026)
 Table 67. Global Parenteral PrEP Revenue (US$ Million) by Application (2027–2032)
 Table 68. Global Parenteral PrEP Revenue Market Share by Application (2021–2026)
 Table 69. Global Parenteral PrEP Revenue Market Share by Application (2027–2032)
 Table 70. Global Parenteral PrEP Price (US$/Dose) by Application (2021–2026)
 Table 71. Global Parenteral PrEP Price (US$/Dose) by Application (2027–2032)
 Table 72. Gilead Sciences Company Information
 Table 73. Gilead Sciences Description and Business Overview
 Table 74. Gilead Sciences Parenteral PrEP Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
 Table 75. Gilead Sciences Parenteral PrEP Product
 Table 76. Gilead Sciences Recent Developments/Updates
 Table 77. ViiV Healthcare Company Information
 Table 78. ViiV Healthcare Description and Business Overview
 Table 79. ViiV Healthcare Parenteral PrEP Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
 Table 80. ViiV Healthcare Parenteral PrEP Product
 Table 81. ViiV Healthcare Recent Developments/Updates
 Table 82. Key Raw Materials Lists
 Table 83. Raw Materials Key Suppliers Lists
 Table 84. Parenteral PrEP Distributors List
 Table 85. Parenteral PrEP Customers List
 Table 86. Parenteral PrEP Market Trends
 Table 87. Parenteral PrEP Market Drivers
 Table 88. Parenteral PrEP Market Challenges
 Table 89. Parenteral PrEP Market Restraints
 Table 90. Research Programs/Design for This Report
 Table 91. Key Data Information from Secondary Sources
 Table 92. Key Data Information from Primary Sources
 Table 93. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Parenteral PrEP
 Figure 2. Global Parenteral PrEP Market Value by Type (US$ Million), 2021–2032
 Figure 3. Global Parenteral PrEP Market Share by Type: 2025 & 2032
 Figure 4. Cabotegravir Product Picture
 Figure 5. Lenacapavir Product Picture
 Figure 6. Other Product Picture
 Figure 7. Global Parenteral PrEP Market Value by Dosing Interval (US$ Million), 2021–2032
 Figure 8. Global Parenteral PrEP Market Share by Dosing Interval: 2025 vs 2032
 Figure 9. Short-interval Injections Product Picture
 Figure 10. Monthly Injections Product Picture
 Figure 11. Quarterly Injections Product Picture
 Figure 12. Global Parenteral PrEP Market Value by Drug Properties (US$ Million), 2021–2032
 Figure 13. Global Parenteral PrEP Market Share by Drug Properties: 2025 vs 2032
 Figure 14. Original Drug Product Picture
 Figure 15. Generic Drug Product Picture
 Figure 16. Global Parenteral PrEP Market Value by Application (US$ Million), 2021–2032
 Figure 17. Global Parenteral PrEP Market Share by Application: 2025 & 2032
 Figure 18. Subcutaneous Use
 Figure 19. Intramuscular Use
 Figure 20. Global Parenteral PrEP Revenue, (US$ Million), 2021 vs 2025 vs 2032
 Figure 21. Global Parenteral PrEP Market Size (US$ Million), 2021–2032
 Figure 22. Global Parenteral PrEP Sales (K Dose), 2021–2032
 Figure 23. Global Parenteral PrEP Average Price (US$/Dose), 2021–2032
 Figure 24. Parenteral PrEP Report Years Considered
 Figure 25. Parenteral PrEP Sales Share by Manufacturers in 2025
 Figure 26. Global Parenteral PrEP Revenue Share by Manufacturers in 2025
 Figure 27. Top 5 and Top 10 Global Parenteral PrEP Players: Market Share by Revenue in Parenteral PrEP in 2025
 Figure 28. Parenteral PrEP Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
 Figure 29. Global Parenteral PrEP Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Figure 30. North America Parenteral PrEP Sales Market Share by Country (2021–2032)
 Figure 31. North America Parenteral PrEP Revenue Market Share by Country (2021–2032)
 Figure 32. United States Parenteral PrEP Revenue Growth Rate (US$ Million), 2021–2032
 Figure 33. Canada Parenteral PrEP Revenue Growth Rate (US$ Million), 2021–2032
 Figure 34. Europe Parenteral PrEP Sales Market Share by Country (2021–2032)
 Figure 35. Europe Parenteral PrEP Revenue Market Share by Country (2021–2032)
 Figure 36. Germany Parenteral PrEP Revenue Growth Rate (US$ Million), 2021–2032
 Figure 37. France Parenteral PrEP Revenue Growth Rate (US$ Million), 2021–2032
 Figure 38. U.K. Parenteral PrEP Revenue Growth Rate (US$ Million), 2021–2032
 Figure 39. Italy Parenteral PrEP Revenue Growth Rate (US$ Million), 2021–2032
 Figure 40. Russia Parenteral PrEP Revenue Growth Rate (US$ Million), 2021–2032
 Figure 41. Asia Pacific Parenteral PrEP Sales Market Share by Region (2021–2032)
 Figure 42. Asia Pacific Parenteral PrEP Revenue Market Share by Region (2021–2032)
 Figure 43. China Parenteral PrEP Revenue Growth Rate (US$ Million), 2021–2032
 Figure 44. Japan Parenteral PrEP Revenue Growth Rate (US$ Million), 2021–2032
 Figure 45. South Korea Parenteral PrEP Revenue Growth Rate (US$ Million), 2021–2032
 Figure 46. India Parenteral PrEP Revenue Growth Rate (US$ Million), 2021–2032
 Figure 47. Australia Parenteral PrEP Revenue Growth Rate (US$ Million), 2021–2032
 Figure 48. China Taiwan Parenteral PrEP Revenue Growth Rate (US$ Million), 2021–2032
 Figure 49. Southeast Asia Parenteral PrEP Revenue Growth Rate (US$ Million), 2021–2032
 Figure 50. Latin America Parenteral PrEP Sales Market Share by Country (2021–2032)
 Figure 51. Latin America Parenteral PrEP Revenue Market Share by Country (2021–2032)
 Figure 52. Mexico Parenteral PrEP Revenue Growth Rate (US$ Million), 2021–2032
 Figure 53. Brazil Parenteral PrEP Revenue Growth Rate (US$ Million), 2021–2032
 Figure 54. Argentina Parenteral PrEP Revenue Growth Rate (US$ Million), 2021–2032
 Figure 55. Colombia Parenteral PrEP Revenue Growth Rate (US$ Million), 2021–2032
 Figure 56. Middle East and Africa Parenteral PrEP Sales Market Share by Country (2021–2032)
 Figure 57. Middle East and Africa Parenteral PrEP Revenue Market Share by Country (2021–2032)
 Figure 58. Turkey Parenteral PrEP Revenue Growth Rate (US$ Million), 2021–2032
 Figure 59. Saudi Arabia Parenteral PrEP Revenue Growth Rate (US$ Million), 2021–2032
 Figure 60. UAE Parenteral PrEP Revenue Growth Rate (US$ Million), 2021–2032
 Figure 61. Global Sales Market Share of Parenteral PrEP by Type (2021–2032)
 Figure 62. Global Revenue Market Share of Parenteral PrEP by Type (2021–2032)
 Figure 63. Global Parenteral PrEP Price (US$/Dose) by Type (2021–2032)
 Figure 64. Global Sales Market Share of Parenteral PrEP by Application (2021–2032)
 Figure 65. Global Revenue Market Share of Parenteral PrEP by Application (2021–2032)
 Figure 66. Global Parenteral PrEP Price (US$/Dose) by Application (2021–2032)
 Figure 67. Parenteral PrEP Value Chain
 Figure 68. Channels of Distribution (Direct Vs Distribution)
 Figure 69. Bottom-up and Top-down Approaches for This Report
 Figure 70. Data Triangulation
 Figure 71. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic

$2900

Single User License
Electronic

$4350

Multi User License
Electronic

$5800

Enterprise License
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Novocure

SIMILAR REPORTS

Global Drugs for PrEP Market Research Report 2024
Global Injectable HIV Medication Market Research Report 2024
Global Long acting PrEP Market Research Report 2024
Global Pre Exposure Prophylaxis PrEP Market Research Report 2024
Global Injectable HIV Treatment Market Research Report 2024
Pre Exposure Prophylaxis Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Long acting Anti HIV Drugs Market Research Report 2024
Global Sustained Release Injectables Market Research Report 2024
Global Parenteral Nutrition Preparation Market Research Report 2024
Global Total Parenteral Nutrition Preparation Market Research Report 2024
Global Parenteral Drugs Market Research Report 2024
Global Plastic Pre Filled Syringes Market Research Report 2024
Global Parenteral Packaging Market Research Report 2024
Global Microsphere Injection Preparation Market Research Report 2024
Implantable Drug Delivery Devices Market
Global Total Parenteral Nutrition TPN Market Research Report 2024
Global Paclitaxel Injection Market Insights Forecast to 2030
Global Enfuvirtide for Injection Market Research Report 2024
Global Premade Lentivirus and Custom Lentivirus Production Services Market Research Report 2024
Global Non LVP Parenterals Products Market Insights Forecast to 2030
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions